Benzodiazepine Abuse, Benzodiazepine Dependence, Substance Use Disorders
Conditions
Keywords
Primary Health Care, Benzodiazepines, Substance Use Disorder, Addiction, Prescription Drugs
Brief summary
Benzodiazepines and benzodiazepine-like hypnotics (z-drugs) are prevalent and addictive narcotics. Guidelines recommend restricted prescription of these drugs for anxiety and insomnia. The majority of benzodiazepine prescriptions are written for these disorders by physicians (GPs) in primary health care. Primary health care is thus an important arena for efforts to reduce access to benzodiazepines in order to lower the number of new users and users at risk of dependency. This trial evaluates whether a brief educational intervention in primary health care followed by 12 months of feedback on prescription data changes the prescription of benzodiazepines and benzodiazepine-like hypnotics.
Detailed description
Background: Benzodiazepines and the benzodiazepine-like hypnotics, often called z-drugs (hereafter benzodiazepines) are common and addictive narcotic drugs that can be obtained by prescription. Even short-term prescription can become a long-term problem, leading to tolerance and dependency, as well as adverse effects, including cognitive disturbance and decline, behavioral problems, emergency visits, accidents, suicide, and drug-related mortality. Guidelines restrict prescription of these drugs for anxiety and insomnia. The majority of benzodiazepine prescriptions are written for these disorders by physicians in primary health care. Primary health care is thus an important arena for efforts to reduce access to benzodiazepines in order to lower the number of new users and users at risk of dependency. Aim: This randomized controlled trial tests whether a brief educational intervention in primary health care followed by 12 months of feedback on prescription data changes prescriptions of benzodiazepines and benzodiazepine-like hypnotics. Methods: Primary health care centers will be invited to participate in the study. Centers that express interest in participating, meet the inclusion criteria, and do not meet the exclusion criteria will be randomized to the intervention or the control group. Personnel at the intervention centers will participate in a brief educational intervention followed by 12 months of regular feedback on benzodiazepine prescriptions that are written at the center. Personnel in an active control group will receive written information on treatment guidelines but will not receive the onsite educational intervention or prescription feedback. Data on characteristics of participating primary health care centers, as well as on prescriptions before the intervention and during and after the 12-month follow-up period, will be gathered from regional health care registers and databases and statistically analyzed.
Interventions
Educational intervention and targeted feedback on prescription of benzodiazepines and benzodiazepine-like hypnotics
Written information on treatment guidelines.
Sponsors
Study design
Masking description
Karolinska Trial Alliance (KTA) will conduct the randomization. The administrator at KTA who conducts the randomization will be blinded to the intervention.
Intervention model description
Randomized controlled trial
Eligibility
Inclusion criteria
for primary health care centers: * Employs at least two full-time physicians * Has at least 3000 patients * Has a regional care agreement (contract)
Exclusion criteria
for primary health care centers: * In operation for less than 12 months * Participated in an intervention to reduce benzodiazepine prescriptions in the last 12 months
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Prescriptions of benzodiazepines and benzodizepine-like hypnotics | 12 months | Change in total prescriptions |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| New prescriptions of benzodiazepines and benzodiazepine-like hypnotics | 12 months | Change in new prescriptions |
Countries
Sweden